Flying high on Elan deal, Alkermes gets to work on Big Pharma project

Alkermes ($ALKS) is taking immediate occupancy of an Elan Drug Technologies' Athalone, Ireland, facility following its $1 billion acquisition of the latter's drug technology business. Alkermes disclosed on Monday it will manufacture a drug for a Big Pharma company at the Athalone plant.

The company, now larger and more diversified, is in the enviable position of still deriving much of its near-term revenue from royalties tied to its drug-delivery technology platforms, but it will also ratchet up the development of its own drugs, according to The Street.

Alkermes expects an additional $15 million to $20 million in annual revenues by 2016 from the manufacturing deal with the Big Pharma outfit, which the firm declined to name.

Alkermes Chairman Shane Cooke told Reuters that he sees opportunities for similar deals, but they're not Alkermes' core business. The company aims to harness the bulk of its efforts on advancing new and improved meds, which it can produce and market on its own.

- here's The Street's take
- see the Reuters report


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.